Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amelogenin
- Development stage
- Phase 4
- Lead developer
- Libo Biotechnology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Amelogenin is an extracellular matrix protein essential for normal tooth development, particularly in enamel formation. It separates and supports mineral crystals as they grow during enamel development. Amelogenin self-assembles into globular aggregates and interacts with various cells involved in wound healing processes. It has been used clinically for periodontal regeneration, wound healing, and bone regeneration applications.
- Brand names
- Emdogain
- Other names
- Enamel Matrix DerivativeEMDEnamel Matrix ProteinsEMPLeucine-rich amelogenin peptideLRAPTyrosine-rich amelogenin peptideTRAPPorcine enamel matrix proteins
Beyond the preview
Go deeper on amelogenin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amelogenin.